Elanco Animal Health Stock Price, News & Analysis

Elanco has introduced Bovaer® (3-NOP), a new feed ingredient for dairy cows that offers a dual benefit of environmental stewardship and financial rewards for farmers. This innovative solution allows dairy farmers to reduce greenhouse gas emissions while creating a new revenue stream through carbon credit sales.

The process is facilitated by Elanco's UpLook™ tool, which quantifies emissions reductions, and Athian, a livestock carbon inset marketplace for credit transactions. This development demonstrates that sustainability and profitability can coexist in modern dairy farming, providing a scalable approach to on-farm sustainability interventions.

Elanco Animal Health Incorporated (NYSE: ELAN) has announced the date for its second quarter 2024 financial results. The company will release its results on Thursday, August 8, 2024, followed by a conference call at 8:00 a.m. eastern time. This call will provide an opportunity for the investment community and media to gain further insights into the company's performance.

Investors, media, and the general public can access a live webcast of the conference call through a link that will be posted on Elanco's investor relations website. For those unable to attend the live event, a replay will be made available on the same website shortly after the call concludes.

Elanco has announced that its product Bovaer® (3-NOP) can significantly reduce methane emissions from dairy cows. Research indicates that feeding one tablespoon of Bovaer per lactating cow daily can cut methane emissions by approximately 30%, equating to around 1.2 metric tons of CO2e emissions annually. This reduction is comparable to removing 285,000 cars off the road for a year if applied to a million cows. The reduction in methane emissions can help mitigate climate warming by decreasing greenhouse gas levels.

Merck Animal Health, a division of Merck & Co., announced the completion of its acquisition of Elanco’s aqua business, strengthening its position in the aquaculture industry. This acquisition includes a diverse portfolio of vaccines, anti-parasitic treatments, water supplements, and nutrition products targeted at both warm and cold water species.

Notably, Merck now owns the CLYNAV® DNA-based vaccine, which protects Atlantic salmon against pancreas disease, and IMVIXA®, an anti-parasitic treatment for sea lice. This move leverages Merck’s capabilities to meet the growing global demand for quality protein and food safety, ensuring enhanced customer benefits and public health protection.

Elanco Animal Health (NYSE: ELAN) has completed the sale of its aqua business to Merck Animal Health (NYSE: MRK) for approximately $1.3 billion in cash. Net proceeds of $1.05-$1.1 billion from this transaction are earmarked for debt reduction in the third quarter of 2024. This move allows Elanco to focus on high-value opportunities in pet health and livestock sustainability, while also enhancing financial flexibility. This transaction, combined with cash flow from operations, is expected to reduce Elanco's total debt by $1.3-$1.4 billion by the end of 2024. The company's net debt to adjusted EBITDA ratio is projected to improve from mid-4x in 2024 to high-3x to low-4x in 2025. Additional details will be provided in the second quarter earnings call in August.

Elanco Animal Health has announced major updates regarding FDA approval timelines for two key products: Zenrelia and Credelio Quattro. Zenrelia has completed all major technical sections and expects final approval by late Q3 2024, with a U.S. launch in Q4 2024. However, a safety warning on the label is anticipated to limit initial adoption by 25%. Zenrelia has already been approved in Brazil with further reviews pending in other markets.

Credelio Quattro has completed two of three major technical sections, with a response to an incomplete letter for the third section already submitted. Final approval is expected in Q4 2024, with a U.S. launch in Q1 2025. Elanco has increased its 2024 innovation sales guidance to $400-$450 million, driven by expected launches and strong existing product performance.

On June 26, 2024, Elanco announced that the Food and Drug Administration (FDA) has approved Bovaer, a feed additive that reduces methane emissions in dairy cows by 30%. This approval marks a significant advancement in sustainable agriculture, as methane is a potent greenhouse gas. Bovaer, which is already used in several countries, works by inhibiting a gut enzyme responsible for methane production. Studies confirm that it has no negative health impacts on cows or humans. This initiative is part of Elanco's broader efforts to provide environmentally friendly solutions in animal health.

Elanco Animal Health (NYSE: ELAN) has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 11-12, 2024. Jeff Simmons, the President and CEO, will engage in a fireside chat on June 11 at 2:40 p.m. ET. The event will be webcast live, and a replay will be accessible for 30 days on Elanco's investor website.

Elanco Animal Health has announced the FDA's completion of a multi-year review of Bovaer, a methane-reducing feed ingredient for dairy cattle, confirming its safety and efficacy. Bovaer can reduce methane emissions by about 30%, creating new revenue streams for dairy farmers through carbon credits. Elanco has also expanded its agreement with dsm-firmenich to distribute Bovaer across North America, including Canada and Mexico. This innovation aims to support climate-neutral dairy farming and meet the increasing demand for sustainable products. Bovaer is expected to generate significant value for farmers and the environment, potentially addressing global warming concerns through reduced greenhouse gas emissions.